These updates are republished press releases and communications from members of the Science|Business Network
Pfizer invests $120M in four biotechnological innovation companies
Pfizer Inc. today announced that, during the second half of 2020, it invested a total of $120 million in four clinical-stage biotech companies as part of the Pfizer Breakthrough Growth Initiative (PBGI). Through PBGI, Pfizer is investing up to $500 million in biotechnology companies, providing funding and access to Pfizer’s scientific expertise to help ensure the continuity of promising clinical development programs of potential future strategic interest to Pfizer.
Pfizer’s initial PBGI investments include:
$10 million in Vancouver, BC-based ESSA Pharma (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer.
Seventure Partners has been investing in microbiome innovation since the launch of its 2014 Health for Life Fund and will now extend reach of its latest fund due to so much interest (Getty Images) European life sciences investment firm Seventure Partners has extended the final close of its second microbiome innovation fund and increased focus on advances in the skin microbiome space.
Seventure Partners had been investing in microbiome innovation since the launch of its Health For Life Fund in 2014, where it invested €160m across 20 cutting-edge companies – Enterome, Vedanta Biosciences and BiomX, among others. In March 2019, Seventure Partners launched its Health For Life Fund II, making a further €200m+ available for investment in the microbiome and nutrition space – a fund that was recently extended.
Pfizer makes first investments through breakthrough growth fund pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
PureTech Founded Entity Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc. Michael Vincent, M.D., Ph.D., Chief Scientific Officer, Inflammation & Immunology Research Unit at Pfizer, to join Vedanta s Scientific Advisory Board
PureTech Health plc (LSE: PRTC, NASDAQ: PRTC) ( PureTech or the Company ), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases , is pleased to note that its Founded Entity, Vedanta Biosciences, today announced that Pfizer Inc. (NYSE: PFE) has made a $25 million investment in Vedanta, as part of the Pfizer Breakthrough Growth Initiative . Vedanta intends to use the proceeds to fund a Phase 2 study of VE202 in inflammatory bowel disease (IBD), which it plans to initiate in 2021.